Yet little is known about whether and how multi-sensory innate threat cues are integrated and conveyed thalamus and external lateral parabrachial nucleus in the brainstem respond to multi-sensory threat cues

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. without compromising strategic control and biotech fundraising credibility? into sustainable progress and stronger biotech fundraising credibility. Why Ambition Naturally Expands in Biotech Companies 👉 Ambition in biotech is data-driven. In biotech, disciplined decisions today build strategic focus, execution clarity, and stronger biotech

👉 In early-stage biotech, activity often feels like strategy. At the same time, the team is preparing for biotech fundraising. in biotech is not complexity. In early-stage biotech, resources are finite. Capital is limited. How Strategic Overload Weakens Biotech Fundraising Signal 👉 Biotech fundraising is not only an evaluation

Before returning to academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech Hamm's lab - and why the committee said G proteins had already won their Nobel Prize 12:39 Co-founding CUE Biotech and Caden Biosciences - allosteric modulator screens and G-protein C-terminal peptide tools Annette worked in industry, academia and her entrepreneurial side led her to three companies, Cue Biotech

GPCR — Scaling Biotech Beyond the Bench Turning scientific excellence into scalable organizations. Leadership 👉 Ambition is the default setting of biotech. This is the hidden cost of ambition in biotech leadership. Not failure. Not poo Attila Foris Mar 2 The Real Cost of Strategic Overload in Biotech 👉 In early-stage biotech, At the same time, the team is preparing for biotech fundraising.

Transform your biotech idea or data into a clear, strategic roadmap with aligned biology, timelines, Home About Services News Get in Touch Welcome Biotech Growth Wherever You Are in Discovery—Let’s Build Biotech teams often tell me: “We have too many CROs and not enough clarity.” How I Help Biotechs Accelerate GPCR Discovery with Clarity, Speed & Confidence Decisions, Not More Data I work with early-stage biotechs—typically preclinical through IND-enabling—who need strategic clarity